Xinxiang Chemical Fiber (000949.SZ) issued a profit warning, expecting a net profit of 216 million to 280 million yuan for the full year of 2024, turning losses into profits compared to the previous year.
Xinxiang Chemical Fiber (000949.SZ) released its 2024 performance forecast, expecting the full year attributable to shareholders of the listed company...
Xinxiang Chemical Fiber (000949.SZ) released its performance forecast for the year 2024, expecting a net profit attributable to shareholders of the listed company of 216 million to 280 million yuan for the full year, turning a profit from a loss compared to the same period last year.
Compared to the same period last year, the company's net profit for the reporting period increased significantly, mainly due to the increase in profits from the main product, biomass cellulose filament. Sales of biomass cellulose filament in the reporting period increased compared to the same period last year, while a decrease in raw material and energy prices led to a reduction in product unit costs, an increase in product gross profit margin, and a significant increase in gross profit.
Related Articles

CHINFMINING(01258): Regarding the tailings dam incident, Qianbi Xi wet method has already fully fulfilled the repair and governance obligations in accordance with government instructions.

A-share hot topics in the evening | NVIDIA invests $5 billion in Intel

Energizer Medicine-B (02595): Hong Kong public offering oversubscribed by 2662.79 times, net proceeds from global offering approximately 1.67 billion Hong Kong dollars.
CHINFMINING(01258): Regarding the tailings dam incident, Qianbi Xi wet method has already fully fulfilled the repair and governance obligations in accordance with government instructions.

A-share hot topics in the evening | NVIDIA invests $5 billion in Intel

Energizer Medicine-B (02595): Hong Kong public offering oversubscribed by 2662.79 times, net proceeds from global offering approximately 1.67 billion Hong Kong dollars.

RECOMMEND

Three-Year R&D Spend Drains RMB 2.4 Billion, Urgent Cash Needs Drive Maiwei Biotech Back to Hong Kong Amid Compliance Scrutiny
18/09/2025

Why Generating Profit Remains Challenging for Lidar Companies
18/09/2025

SEC Adopts Landmark Rule to Restrict Shareholder Class Actions in Bid to Revive IPO Market
18/09/2025